Skip to main content
OpenTrials
Completed

NCT Number: NCT00995839

Terlipressin in Septic Shock: Effects on Microcirculation

The present study was conducted as a prospective, randomized study to investigate the effects of vasopressin receptor agonists terlipressin and vasopressin on systemic hemodynamics and microcirculation in patients with catecholamine-dependent septic shock.

Completed

Looking for future studies?

Notify Me

Key information

About this study

60 septic shock patients requiring norepinephrine to maintain mean arterial pressure between 65 and 75 mmHg despite adequate volume resuscitation will be enrolled in the study. After an initial hemodynamic resuscitation aimed at achieve a mean arterial pressure between 65 and 75 mmHg and normovolemia, patients will be randomly allocated to be treated with either a) intravenous administration of terlipressin 1 µg∙kg-1∙h-1 for 6 hrs, b) intravenous administration of arginine vasopressin 0.04 UI∙min-1 for 6 hrs, c) intravenous administration of terlipressin bolus dose of 0.5 mg (each n = 20). In all groups open label norepinephrine will be additionally administered to maintain a mean arterial pressure (MAP) between 65 and 75 mmHg, if necessary. Data from right heart catheterization and sublingual microvascular network will be obtained just before randomization (baseline) and then after 6 hours in the vasopressin, terlipressin infusion and terlipressin bolus groups.

The sublingual microvascular network will be studied using the sidestream dark field (SDF)imaging. The device will be applied on the lateral side of the tongue, in an area approximately 2-4 cm from the tip of the tongue. Sequences of 10 secs from eight adjacent areas will be recorded on disk using a personal computer. These sequences will be later analyzed by an investigator blinded to the patient's diagnosis and therapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of septic shock
  • Vasopressor support to maintain mean arterial pressure (MAP) between 65 and 75 mmHg despite adequate volume resuscitation (pulmonary artery occlusion pressure = 13-18 mmHg and central venous pressure = 8-12 mmHg)

Exclusion criteria

  • Pregnancy
  • Age < 18 years
  • Present or suspected acute mesenteric ischemia
  • Vasospastic diathesis (e.g. Raynaud's syndrome or related diseases)

Treatment and study plan

continuous infusion of terlipressin

Drug

Intravenous continuous infusion of terlipressin 1 µg•kg-1•h-1 for 6 hrs

Arginine vasopressin

Drug

Intravenous continuous infusion of arginine vasopressin 0.04 UI•min-1 for 6 hrs

terlipressin bolus administration

Drug

intravenous terlipressin bolus administration at the dose of 0.5 mg

Primary outcomes

  1. Systemic hemodynamic and Microcirculatory flow index of small and medium vessels (MFI)

    Time frame: over a period of 6 hrs from the time of randomization

  2. Oxygen transport variables

    Time frame: over a period of 6 from the time of randomization

Secondary outcomes

  1. Acid-base homeostasis

    Time frame: over a period of 6 hrs from the time of randomization

  2. Functional capillary density (mm/mm2) (FCD)

    Time frame: over a period of 6 hrs from the time of randomization

  3. De Backer score

    Time frame: over a period of 6 hrs from the time of randomization

  4. Perfused Vessel Density (PVD) (mm/mm2)

    Time frame: over a period of 6 hrs from the time of randomization

  5. Proportion of Perfused vessels (%) (PPV)

    Time frame: over a period of 6 hrs from the time of randomization

Sponsors and collaborators

Lead sponsor

University of Roma La Sapienza

Other

Registry information

Official study title

Vasopressin Receptor Agonists in Septic Shock: Effects on Microcirculation

Important dates

Study start
2008
Primary completion
2010
Study completion
2010
First posted
Oct 15, 2009
Registry last updated
Feb 4, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.